Friday, October 22, 2021 3:26:20 PM
The instructions very clearly state how to operate the device safely and how to deploy the safety sheath in a safe manner. I do not want to receive medical care from someone who is incapable of following these very clear and simple instructions.
Part of the FDA approval process and review and acceptance of safety criteria, and their approval of this product (and our Symjepi product which uses a very similar device) shows what the FDA's opinion is with regard to safety of this device.
Next, someone should complain to the FDA that the device is an eye hazard because it doesn't say "Do not push the device into your eyeball."
It does, however, say:
"'- Never put thumb, fingers, or hand over the exposed needle. Failure to follow these instructions may result in a
needlestick injury"
It also says:
"Right after the injection, using one hand with fingers behind the
needle, slide the safety guard over the needle."
And, similarly, as you noted below:
"'- Immediately after injection, using one hand with fingers behind the needle, slide the safety guard over the needle. Do not
use two hands to activate the safety guard.'"
Don't forget:
"Stress to patients the importance of familiarizing themselves with the device and its operation prior to experiencing an emergency situation."
If the user (medical professional or not) follows the simple instructions, the only needle contact is the intentional and necessary needle contact with the PATIENT ONLY.
I believe your "evidence" is a gross and blatant misinterpretation of the facts to try to besmirch the product, the company, and me. I again ask that others review all the information in this post, yours and mine, and judge for themselves.
Message in reply to:
Post 3501 " No needle contact by medical personnel." This is not true as per the FDA document provided. You asked for evidence and I give you the FDA.
Also, if this is to be used my non medical professionals so the concerns I have laid out are valid and backed by this document. This has been completely ignored.
Information below was pulled from link at bottom of post which is instructions on Zimhi.
'Risk of Accidental Needlestick Injury: After use, the ZIMHI needle is exposed until the safety guard is deployed. Stress to patients the importance of familiarizing themselves with the device and its operation prior to experiencing an emergency situation, and to immediately seek medical attention should a needlestick occur.'
'- Embed the needle completely before transferring the thumb to the syringe plunger.'
'- Immediately after injection, using one hand with fingers behind the needle, slide the safety guard over the needle. Do not
use two hands to activate the safety guard.'
'- Never put thumb, fingers, or hand over the exposed needle. Failure to follow these instructions may result in a
needlestick injury. If an accidental needlestick occurs, get medical help immediately [see Warnings and Precautions
(5.4)].'
'- Do NOT attempt to re-cap the needle with the needle cap once it has been removed [see Warnings and Precautions
(5.4)].'
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212854s000lbl.pdf#:~:text=%285.3%29%20%E2%80%A2%20Risk%20of%20Accidental%20Needlestick%20Injury%3A%20After,seek%20medical%20attention%20should%20a%20needlestick%20occur.%20%285.4%29
Recent ADMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:50:07 PM
- Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus • GlobeNewswire Inc. • 09/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 09:20:33 PM
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/21/2023 01:15:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:38:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 08/10/2023 08:03:30 PM
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/04/2023 05:43:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:59:45 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/03/2023 08:55:39 PM
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/02/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 09:01:12 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/28/2023 08:58:05 PM
- Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert • GlobeNewswire Inc. • 07/28/2023 12:30:00 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/27/2023 10:08:01 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/27/2023 01:17:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:15:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/13/2023 08:37:24 PM
- Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/26/2023 11:30:00 AM
- Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention • GlobeNewswire Inc. • 06/22/2023 11:30:00 AM
- Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals • GlobeNewswire Inc. • 05/25/2023 08:26:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM